{"nctId":"NCT02015234","briefTitle":"12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients","startDateStruct":{"date":"2013-12"},"conditions":["Primary Fibromyalgia"],"count":158,"armGroups":[{"label":"TNX-102 SL","type":"EXPERIMENTAL","interventionNames":["Drug: TNX-102 SL"]}],"interventions":[{"name":"TNX-102 SL","otherNames":["cyclobenzaprine HCl"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. The patient met all prior inclusion and exclusion requirements for Study F202 (NCT01903265) originally, and has had no intervening medical conditions, increased suicidal ideation, or requirements for concomitant medications that preclude exposure to TNX-102 SL or enrollment in the extension study.\n2. The patient completed expected dosing in F202 (NCT01903265) defined as taking study medication up to Week 12, with at least 70% compliance with medication usage (based on responses from daily IVRS calls recorded during the F202 study (NCT01903265)) and no major protocol violations.\n3. The patient has provided written informed consent to participate in this extension protocol.\n\nExclusion Criteria:\n\nNone","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Newly-emergent Adverse Events (NEAEs) During Treatment With TNX-102 SL Tablets Taken Daily at Bedtime Over 12 Months in Patients With Fibromyalgia.","description":"NEAEs and Serious Adverse events (SAEs) were collected and are coded using the latest version of the Medical Dictionary for Regulatory Activities (MedDRA).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Numerical Rating Scale (NRS) Assessments of Average Pain Based on 24 Hour Recall","description":"The NRS for average pain was an 11-point scale (0=no pain → 10=worst pain imaginable) that was assessed on a 24-hour recall basis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"2.29"},{"groupId":"OG001","value":"5.0","spread":"2.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"1.96"},{"groupId":"OG001","value":"-0.2","spread":"1.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"1.86"},{"groupId":"OG001","value":"-0.3","spread":"1.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"2.18"},{"groupId":"OG001","value":"-0.2","spread":"2.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"2.36"},{"groupId":"OG001","value":"0.0","spread":"1.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"2.08"},{"groupId":"OG001","value":"-0.0","spread":"2.26"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Numerical Rating Scale (NRS) Assessments of Average Pain Based on a 7 Day Recall","description":"The NRS for average pain over the past 7 days was an 11-point scale (0=no pain → 10=worst pain imaginable) that was assessed on a 7-day recall basis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":"2.09"},{"groupId":"OG001","value":"4.8","spread":"2.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.68"},{"groupId":"OG001","value":"0.1","spread":"1.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"1.67"},{"groupId":"OG001","value":"0.1","spread":"1.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"2.06"},{"groupId":"OG001","value":"0.2","spread":"2.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"2.33"},{"groupId":"OG001","value":"0.0","spread":"2.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.72"},{"groupId":"OG001","value":"0.2","spread":"1.84"}]}]}]},{"type":"SECONDARY","title":"Responder Analysis of Patient's Global Impression of Change (PGIC)","description":"PGIC is a fibromyalgia-specific validated instrument to gauge the patient's assessment of change in condition.The scores are categorized as provided below. A responder was defined by a score of 1 (very much improved), or 2 (much improved).\n\n1. = Very much improved\n2. = Much improved\n3. = Minimally improved\n4. = No change\n5. = Minimally worse\n6. = Much worse\n7. = Very much worse","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"25","spread":null}]},{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"29","spread":null}]},{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"26","spread":null}]},{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"27","spread":null}]},{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"32","spread":null}]},{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":79},"commonTop":["Hypoaesthesia oral","Sinusitis","Fatigue","Product taste abnormal","Glossodynia"]}}}